Lv34
380 积分 2025-03-26 加入
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
9天前
已完结
Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors
13天前
已关闭
A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects
27天前
已关闭
SHR-2004, A Novel Humanised Monoclonal Antibody Targeting Factor XI (FXI), For Preventing Venous Thromboembolism (VTE) In Patients Undergoing Surgery For Ovarian Cancer: A Randomised, Active-Control Phase 2 Study
1个月前
已关闭
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism
1个月前
已完结
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
1个月前
已完结
SHR-2004, A Novel Humanised Monoclonal Antibody Targeting Factor XI (FXI), For Preventing Venous Thromboembolism (VTE) In Patients Undergoing Surgery For Ovarian Cancer: A Randomised, Active-Control Phase 2 Study
1个月前
已关闭
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?
1个月前
已完结
Asundexian versus Apixaban in Patients with Atrial Fibrillation
1个月前
已完结
皖公网安备34019202002308
